ARTICLE | Company News
Pfizer acquires two meningitis vaccines from GSK
June 23, 2015 1:38 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will sell quadrivalent meningitis vaccines Nimenrix and Mencevax to Pfizer Inc. (NYSE:PFE) for EUR 115 million ($130.2 million) to address competition concerns raised by the European Commission.
Earlier this year, GSK acquired meningitis vaccines Menveo and Bexsero through an asset swap with Novartis AG (NYSE:NVS; SIX:NOVN). The EC cleared the asset swap after GSK agreed to sell Nimenrix and Mencevax. ...